Navigation Links
Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Date:9/2/2009

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidates will be presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at The Moscone Center in San Francisco on September 12-15, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Fidaxomicin abstracts and speakers include:

    "Low Recurrence Rate among Patients with C. difficile Infection (CDI)
    Treated with Fidaxomicin (FDX)"
    Poster Presentation: Yoav Golan, M.D., M.S.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1639 in Hall B

    "Restriction Endonuclease Analysis (REA) Typing of Clostridium difficile
    in a Phase 3 Treatment Trial of Fidaxomicin vs Vancomycin: Decreased Cure
    Rate for Epidemic BI/NAP1/027 Strain"
    Poster Presentation: Dale N. Gerding, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1642 in Hall B

    "Comparative Fidaxomicin Susceptibilities of Isolates Collected at
    Baseline, Failure, and Recurrence from Patients in a Phase III Trial of
    Clostridium difficile Infection (CDI)"
    Poster Presentation: Ellie J. Goldstein, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1641 in Hall B

    "Safety of Fidaxomicin Versus Vancomycin in Treatment of Clostridium
    difficile Infection"
    Poster Presentation: Sherwood L. Gorbach, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1640 in Hall B

    "Pharmacokinetics/Pharmacodynamics (PK/PD) of Fidaxomicin in Treatment of
    Clostridium difficile Infection (CDI)"
    Poster Presentation: Pam Sears, Ph.D.
    Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
    Presentation number: A1-1949 in Hall D

    "Rifampin, Rifaximin, OPT-80 and Tigecycline Susceptibility of C.
    difficile Strains from Canada and Italy: Rifamycin Resistance Entirely
    Predicted by Rifampin E-test with Divergent Rifamycin Resistance among the
    Two Countries"
    Poster Presentation:  Mark A. Miller, M.D.
    Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
    Presentation number: C2-1958 in Hall D

    "Acquisition and Overgrowth of Vancomycin-Resistant Enterococci in
    Patients Treated with Fidaxomicin (FDX) Versus Vancomycin (VAN) for
    Clostridium difficile Infection"
    Oral Presentation: Curtis J. Donskey, M.D.
    Tuesday, September 15, 2009 10:45am-11:00am Pacific Time
    Presentation number: K-1915 in Room 131

    Prulifloxacin abstracts and speakers include:

    "Prulifloxacin, a New Fluoroquinolone Treatment for Traveler's Diarrhea"
    Poster Presentation: Prof. Robert Steffen, M.D.
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: L1-1643 in Hall B

    "Recommended Ulifloxacin (Prulifloxacin) MIC Quality Control Ranges for
    Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study
    Design"
    Poster Presentation: J.M. Streit
    Monday, September 14, 2009 11:15am-1:15pm Pacific Time
    Presentation number: D-1433 in Hall B

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):